Publications

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Download PDF
Resource: STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

.

Related Articles

Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study

Link
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade

Link